Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Fiche publication
Date publication
juin 2020
Journal
Targeted oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique
Tous les auteurs :
Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, Birtle A, Kramer G, Kalinka E, Spaëth D, Feyerabend S, Matveev V, Lefresne F, Lukac M, Wapenaar R, Costa L
Lien Pubmed
Résumé
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials.
Référence
Target Oncol. 2020 Jun 4;: